[The Leap of K-Bio] South Korean Bio Industry Analysis: Moving Beyond Biosimilars and CDMO to a Global Novel Drug Powerhouse, Is It Time to Invest?
K-BIO INDUSTRY INFRASTRUCTURE GLOBAL MEDICAL SOLUTIONS & CDMO POWERHOUSE If one sector stands out as the next-generation engine of national growth aligned with global aging demographics, it is undeniably the 'Bio' industry. While South Korea’s bio sector previously relied on vague expectations centered around small-scale ventures, today's K-Bio has secured a pivotal position in the global supply chain, propelled by heavy corporate capital and unrivaled manufacturing capability. 1. Current Landscape: Why Biosimilars and CDMO? The ecosystem of the South Korean bio industry is heavily concentrated around two structural pillars: Contract Development and Manufacturing Organization (CDMO) and Biosimilars (biopharmaceutical generics). This strategic direction was chosen to mitigate the astronomical capital and lengthy timelines demanded by novel drug development, allowing Korea to fully leverage its world-class quality control and mass-manufacturing capabili...